A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation

• Status: Withdrawn
• Trial end date: 2023-05-31

Summary

The primary purpose of this study is to determine the overall response rate (ORR) during induction therapy with the combination of ixazomib, thalidomide and low-dose dexamethasone in specific time points.

• Phase: Phase 2

Details

• Lead Sponsor: Takeda
• Treatments: BB 1101; Dexamethasone; Dexamethasone acetate; Glycine; Ixazomib; Thalidomide